BRIEF published on 04/07/2026 at 07:05, 4 months 27 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 4 months 27 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 5 months 13 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 5 months 13 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 7 months 23 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 9 months 2 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 11 months 8 days ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 11 months 8 days ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 2 years 1 month ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 2 years 1 month ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 09/04/2026 at 08:02, 1 hour 15 minutes ago Southern Energy Corp. Announces Restricted Share Award Grant
Published on 09/03/2026 at 17:55, 15 hours 22 minutes ago ACCESS Newswire to Participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference in New York on September 10, 2026
Published on 09/03/2026 at 15:00, 18 hours 17 minutes ago Arcus & Core Mobilize for 3,000 Metre Drilling Program at the Touleary VMS Project
Published on 09/03/2026 at 15:00, 18 hours 17 minutes ago Arcus & Core Mobilize for 3,000 Metre Drilling Program at the Touleary VMS Project
Published on 09/04/2026 at 09:05, 11 minutes ago Jackery Unveils Next-Gen Explorer Plus v2 Series at IFA 2026: Up to 60% Smaller with 'Safety First' Reliability
Published on 09/04/2026 at 09:05, 11 minutes ago ALP NAMED OFFICIAL NICOTINE POUCH PARTNER OF MATCHROOM BOXING
Published on 09/04/2026 at 09:00, 16 minutes ago Municipality Finance issues NOK 2 billion notes under its MTN programme
Published on 09/04/2026 at 08:29, 47 minutes ago ENGIE exceeds 10 GW of storage capacity worldwide, driven by summer growth in BESS across Europe
Published on 09/03/2026 at 18:40, 14 hours 36 minutes ago Mersen: Number of shares and voting rights as of August 31, 2026
Published on 09/03/2026 at 18:10, 15 hours 6 minutes ago Eiffage wins the contract to build two steel structures part of the new Merwede Bridge in the Netherlands
Published on 09/03/2026 at 18:02, 15 hours 14 minutes ago Total number of voting rights and shares making up the share capital at August 31, 2026
Published on 09/03/2026 at 18:00, 15 hours 17 minutes ago Kerlink and DataPrint Announce Distribution Partnership To Expand LoRaWAN® Adoption Across France
